18 / 22
Page 106
conferenceseries
.com
Volume 3, Issue 4
J Clin Epigenet
ISSN: 2472-1158
Epigenetics 2017
November 06-08, 2017
EPIGENETICS & CHROMATIN
November 06-08, 2017 | Frankfurt, Germany
2
nd
International Congress on
J Clin Epigenet 2017, 3:4
DOI: 10.21767/2472-1158-C1-003
Epigenetic therapies and the development of personalized treatment of genetic pathologies
Rick Wallace
The Visionetics Institute, USA
D
espite the investment of a substantial amount of technological, financial and academic resources, there has been
minimal progress in the attempt to reduce the mortality rate associated with multitudinous forms of cancer and other
genetic diseases. The advancement in the understanding of epigenetics and its impact on gene expression has introduced a
potential gateway through which early detection of genetically influenced bio-pathologies can be experienced. Through the
use of epigenetic data, it may be possible to detect or even anticipate the disruption of epigenetic networks that subsequently
lead to the development of a number of major pathologies that include chromosomal instability syndromes, cancer and
mental retardation. The introduction of epigenetics as a diagnostic tool may not only create the capacity to detect the
aforementioned pathologies, it may also reveal other pathologies that are caused by epigenetic alterations. There is also great
potential in the development of therapies that are centered in epigenetic processes that include DNA methyl transferase
and histone deacetylases, as well as enzyme inhibitors, all of which have shown anti-tumorigenic promise as it pertains to
certain malignancies. Epigenetics also offers great promise in the area of personalized treatment based on certain genetic
predispositions. The study of epigenetics creates the opportunity to integrate advanced technologies and concepts into the
process of diagnosis, prognosis and therapeutics — ultimately improving on the current dismal results being experienced.